S. Li, Z. Zhou, D. Patel, S. Hinman, Q. Cheng
Luna Innovations Inc,
Keywords: NANOenhanced, SPRi, multiple organ injury, biomarker, sensitivity, Pg/mL, multiplexity
Summary:Major organ injuries such as liver, kidney, heart and lung injuries can lead to high morbidity and mortality in critically ill patients. Advanced noninvasive testing with high sensitivity and specificity is needed to detect specific organ injury particularly at early stages. Current techniques such as PCR, MS, absorption-based assays, ELISA and microfluidic-Luminex, cannot meet such requirements. To address this issue, Luna is developing a multiplex biomarker assay based on nanoenhanced SPRi (NANOeSPRi) technique that is specific and sensitive to a diversity of organ injuries. In this in vitro diagnostic assay, arrays of antibody pairs or aptamer pairs that form a sandwich type complex with proteins or microRNAs biomarkers are used to detect multiple biomarkers simultaneously within a short period of time with significantly improved specificity and limit of detection compared to existing or clinically used tools including ELISA. An assay kit including a biochip, pertinent reagents and buffers will be developed for use in the filed or clinical labs. In Phase I study, Luna has demonstrated the proposed assay with high sensitivity down to 10s pg/mL scale and its multiplexity by the detection of two biomarkers simultaneously, which is being expanded to detect more biomarkers from more organ injuries now. The success of this project will provide a diagnostic product that helps both military and civilian hospitals determine whether a patient has organ injury, thereby allowing the possibility to take early curative intervention. This work is supported by the US Army Medical Research and Materiel Command under Contract No W81XWH-14-C-0146.